Baumer S.A (BALM3) Fair Value & Analysis
Healthcare · BR · Market cap R$254M
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from R$108.80 to R$40.65 (−62.6%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range R$8.02 – R$30.00 · fair‑value band R$30.48 – R$50.81 · the R$26.00 price screens below the R$40.65 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Baumer S.A (BALM3) currently trades at R$26.00, while our model-based Fair Value estimate is R$40.65 — implying the stock looks roughly 56.3% undervalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Baumer S.A generated revenue of R$212M at a net margin of 9.1%. Revenue declined 2.8% year over year. It earns a return on equity of 13.5%. Net debt stands at R$5.4M. Fundamentals as of Jul 5, 2026
Our scenario range runs from R$30.48 (bear case) to R$50.81 (bull case); at R$26.00, the current price sits below that range. The share trades about 13% below its 52-week high and 53% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at 56%, BALM3 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Baumer S.A., together with its subsidiaries, engages in the development, industrialization, trade, production, import, export, and technical assistance in products for hospitals and industries related to the health area in Brazil and internationally. The company offers orthopedic devices, such as conventional prosthesis, spine and neurosurgery, non-conventional prosthesis, trauma, and biomaterials; and hospital equipment, including CSSD, surgical center and ICU, and sterilization process monitoring. It also provides life science equipment comprising pharmaceutical production and research laboratory; bone regeneration consisting of structural, raw material, and specialties; and maintenance, sterilization process monitoring, rental, CME equipment management, technological update, and replacement parts, as well as inspection, qualification, and calibration services. In addition, the company offers the Baumer Academy platform for specialized courses in the areas of hospital equipment, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Baumer S.A reported revenue of R$214M in FY2025 versus R$268M in FY2021, a compound −5.5%/yr. Reported net income was R$18.1M in FY2025, compounding +15.6%/yr from FY2021.
Is BALM3 fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$245.50 | R$42.64 | -83% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Baumer S.A (BALM3) undervalued?
What is the fair value of BALM3?
What is the quality score of BALM3?
What is the revenue of Baumer S.A (BALM3)?
What is the net profit margin of BALM3?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.